Correspondence 0001493152-24-045187 from Ernexa Therapeutics Inc. (ERNA)

Ernexa Therapeutics Inc.
Date: Nov. 13, 2024 · CIK: 0000748592 · Accession: 0001493152-24-045187

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-283003

Date

November 5, 2024

Author

ETERNA

Form

CORRESP

Company

Ernexa Therapeutics Inc.

Letter

Eterna Therapeutics Inc.

Cambridge Street, Suite 18A

Cambridge, MA 02141

(212) 582-1199

November 13, 2024

VIA EDGAR

United States Securities and Exchange Commission

F Street, N.E.

Washington, D.C. 20549

Attention: Daniel Crawford

Re: Eterna Therapeutics Inc.

Registration Statement on Form S-1

Filed November 5, 2024

File No. 333-283003

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Eterna Therapeutics Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above (the “Registration Statement”) be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on November 15, 2024, or as soon thereafter as possible.

Please notify Edwin Astudillo of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at 858.720.8953 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request and/or contact him with any questions.

Regards,
ETERNA
THERAPEUTICS INC.

Show Raw Text

CORRESP
1
filename1.htm

Eterna
Therapeutics Inc.

1035
Cambridge Street, Suite 18A

Cambridge,
MA 02141

(212)
582-1199

November
13, 2024

VIA
EDGAR

United
States Securities and Exchange Commission

100
F Street, N.E.

Washington,
D.C. 20549

Attention:
Daniel Crawford

    Re:
    Eterna
    Therapeutics Inc.

    Registration
    Statement on Form S-1

    Filed
    November 5, 2024

    File
    No. 333-283003

Ladies
and Gentlemen:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Eterna Therapeutics Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above (the “Registration Statement”)
be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on November 15, 2024, or as soon thereafter as possible.

Please
notify Edwin Astudillo of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at 858.720.8953 as soon as possible as
to the time the Registration Statement has been declared effective pursuant to this acceleration request and/or contact him with any
questions.

    Regards,

    ETERNA
    THERAPEUTICS INC.

    By:
    /s/
    Sandra Gurrola

    Name:
    Sandra
    Gurrola

    Title:
    Senior
    Vice President, Finance

SecProbe.io